Scholarlink

<p>Chemotherapies are often given without precision biomarkers, exposing patients to toxic side effects without guaranteed benefit. Here we present chromosomal instability signature biomarkers that identify resistance to platinum-, taxane- and anthracycline-based treatments using a single genomic test. In retrospectively emulated randomized-control biomarker clinical trials using real-world cohorts (<i>n</i> = 840), predicted resistant patients had elevated treatment failure risk for taxane (hazard ratio (HR) of 7.44) and anthracycline (HR of 1.88) in ovarian, taxane (HR of 3.98) and anthracycline (HR of 3.69) in metastatic breast and taxane (HR of 5.46) in metastatic prostate. Nonrandomized emulations showed predictive capacity for platinum resistance in ovarian (HR of 1.46) and anthracycline in sarcoma (HR of 3.59). We demonstrate feasibility using whole-genome sequencing, capture-panel sequencing and cell-free DNA. Our findings highlight the clinical value of chromosomal instability signatures in predicting resistance to chemotherapies across multiple cancer types, with the potential to transform the one-size-fits-all chemotherapy approach into precise, tailored treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Predicting resistance to chemotherapy using chromosomal instability signatures

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月23日

查看全文
  • Joe Sneath Thompson,
  • Laura Madrid,
  • Barbara Hernando,
  • Carolin M. Sauer,
  • Maria Vias,
  • Maria Escobar-Rey,
  • Wing-Kit Leung,
  • Diego Garcia-Lopez,
  • Jamie Huckstep,
  • Magdalena Sekowska,
  • Karen Hosking,
  • Mercedes Jimenez-Linan,
  • Marika A. V. Reinius,
  • Abhipsa Roy,
  • Omar Abdulle,
  • Justina Pangonyte,
  • Harry Dobson,
  • Amy E. Cullen,
  • Dilrini De Silva,
  • David Gómez-Sánchez,
  • Marina Torres,
  • Ángel Fernández-Sanromán,
  • Deborah Sanders,
  • Filipe Correia Martins,
  • Ionut-Gabriel Funingana,
  • Giovanni Codacci-Pisanelli,
  • Miguel Quintela-Fandino,
  • Florian Markowetz,
  • Jason Yip,
  • James D. Brenton,
  • Anna M. Piskorz,
  • Geoff Macintyre

摘要

Chemotherapies are often given without precision biomarkers, exposing patients to toxic side effects without guaranteed benefit. Here we present chromosomal instability signature biomarkers that identify resistance to platinum-, taxane- and anthracycline-based treatments using a single genomic test. In retrospectively emulated randomized-control biomarker clinical trials using real-world cohorts (n = 840), predicted resistant patients had elevated treatment failure risk for taxane (hazard ratio (HR) of 7.44) and anthracycline (HR of 1.88) in ovarian, taxane (HR of 3.98) and anthracycline (HR of 3.69) in metastatic breast and taxane (HR of 5.46) in metastatic prostate. Nonrandomized emulations showed predictive capacity for platinum resistance in ovarian (HR of 1.46) and anthracycline in sarcoma (HR of 3.59). We demonstrate feasibility using whole-genome sequencing, capture-panel sequencing and cell-free DNA. Our findings highlight the clinical value of chromosomal instability signatures in predicting resistance to chemotherapies across multiple cancer types, with the potential to transform the one-size-fits-all chemotherapy approach into precise, tailored treatment.